Synergy Health Discussion Board http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion http://www.iii.co.uk/icons/logos/uk_logo.gif http://www.iii.co.uk tag:iii.co.uk,2003:tst.9530235
Also SYR recently made the list of the 20 most consistent performing stocks in a Societe Generale study which looked at which FTSE stocks an investor could have bought in any month since 1993 and made a positive return on a buy-and-hold total return basis, assuming the stock was held for five years. By mutandis13 ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=9530235&action=detail Thu, 12 Apr 2012 08:58:00 GMT mutandis13 tag:iii.co.uk,2003:tst.9460070
A strategic statement of intent with respect to the US market, but a sensible approach "...By having a small, but low risk entry point into this market, we will be in a position to fully research the requirements of the US healthcare market and set ourselves up for a progressive expansion of the service in 2013..."

There was no mention with respect to the current management, which I would have expected especially given the need for them to discover the differences in the US market.

By mutandis13 ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=9460070&action=detail Wed, 21 Mar 2012 13:22:00 GMT mutandis13 tag:iii.co.uk,2003:tst.9216962
Cash generation continues to be reasonably strong with net debt falling £4m in 3 months.

The only negative, although expected, was "...Whilst the operating environment in Europe continues to be relatively stable, the macroeconomic risks are perceived to have increased..." hence the reorganisation that will cost £2.3m in this financial year to save £2m pa.

Over the past 2 years free cash flow has represented 62% of net debt. This need to be maintained and used to reduce debt, whilst continuing with their progressive dividend policy and place acquisitions on the "back-burner" until the environment in Europe improves. By mutandis13 ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=9216962&action=detail Fri, 27 Jan 2012 09:53:00 GMT mutandis13 tag:iii.co.uk,2003:tst.8949867 http://www.cityam.com/news-and-analysis/best-the-brokers/best-the-brokers-449

Tuesday 15th November 2011, 12:28am

SYNERGY HEALTHCARE
Morgan Stanley rates the provider of sterilisation services to hospitals as “overweight” with a target price of 1,085p, based on stable, defensive growth, opportunities from new regions and acquisitions, a cheap valuation, and expanding margins. Following eight per cent organic growth in its first half results last week, the broker says the risk of cuts hitting hospital budgets as a positive tailwind to growth as clients look for lower, outsourced costs. By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=8949867&action=detail Tue, 15 Nov 2011 04:29:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.8945319 Retains
Overweight Overweight
1,085.00 1,985.00
900
2
GBP
http://www.brokerforecasts.com/companies/SYR/Synergy+Health+PLC By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=8945319&action=detail Mon, 14 Nov 2011 05:12:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.8941703 By Julian Hofmann, 10 November 2011
http://www.investorschronicle.co.uk/2011/11/10/shares/news-and-analysis/synergy-health-makes-progress-SjPfP6JAuZCNg1mNu4DwFN/article.html


Despite NHS procurement problems and an increasingly uncertain economic backdrop, sterilisation specialist Synergy Health managed a steady half-year performance - sales in its core UK market rose 2.9 per cent in the period to £78.2m.
But NHS structural reorganisation is proving challenging for those looking to secure contracts. "We were getting near to the end of the process only to find that senior executives have moved to other hospitals," noted chief executive Richard Steeves. Moreover, procurement delays meant increased working capital, although it was mainly £27.7m of expenditure on new facilities - as well as £9.9m on acquisitions - that boosted the net debt pile in the half to £149.2m from £112.3m.
Meanwhile, Synergy's sedate-looking European sales growth is in stark contrast with that of the Africa & Asia unit - sales there grew 29.8 per cent to £8.2m, with operating profits rose a roughly similar amount to £1.7m. The company has particularly high hopes for China's expansion of free public healthcare. Although Mr Steeves said progress had been slower than expected - partly because the company has had to walk away from deals that involved offering some form of bribe.
Investec Securities expects full-year pre-tax profit of £43.9m, giving EPS of 58.7p (2011:£38.3m/52.6p).
SYNERGY HEALTH (SYR)
ORD PRICE: 814p MARKET VALUE: £450m
TOUCH: 812-814p 12-MONTH HIGH: 1,002p LOW: 759p
DIVIDEND YIELD: 2.0% PE RATIO: 15
NET ASSET VALUE: 522p* NET DEBT: 52%
Half-year to 2 Oct Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p)
2010 139 15.0 21.6 6.00
2011 155 16.6 23.7 6.82
% change +12 +11 +10 +14
Ex-div:16 Nov
Payment:15 Dec
*Includes intangible assets of £253m, or 457p a share
IC VIEW:

Synergy is coping well in tough conditions and the overseas operations - China in particular - are especially promising. So, trading on a forward PE ratio of under 14 times expected earnings, the shares rate long-term good value.

http://www.brokerforecasts.com/companies/SYR/Synergy%20Health%20PLC
Morgan Stanley Synergy Health PLC 11/11/11 05:17
Retains
Overweight Overweight
1,085.00 1,085.00
2
GBP
Jefferies International Synergy Health PLC 10/11/11 11:04
Retains
Buy Buy
1,110.00 1,110.00
2
GBP
Morgan Stanley Synergy Health PLC 10/11/11 11:03
Retains
Overweight Overweight
1,085.00 1,085.00
2
GBP By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=8941703&action=detail Sat, 12 Nov 2011 10:52:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.8931631 ')" target="_new" rel="nofollow">http://www.brokerforecasts.com/companies/SYR/Synergy+Health+PLC

Brewin Dolphin Synergy Health PLC 10/11/11 08:44
Upgrades
Hold Add
1
943.00
943
1
GBP
Charles Stanley Synergy Health PLC 10/11/11 08:24
Reiterates
Buy Buy
1,085.00 1,085.00
2
GBP By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=8931631&action=detail Thu, 10 Nov 2011 07:55:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.8361806
Good cash generation of £83.7m up 9.5%, improved margins by 110 basis points and even 10 basis points up on the first half and a strong closing order book up 8.2% at £920m.

Not surprising then that they gave such a strong outlook

"...We expect to see the Group's overall revenue growth rates reach double digits over the next twelve to eighteen months. Higher revenue growth rates, supported by sustainable improved margins and strong cash generation, leave the business well positioned to continue to deliver its earnings objectives. The new financial year has started strongly..."
By mutandis13 ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=8361806&action=detail Tue, 07 Jun 2011 20:55:00 GMT mutandis13 tag:iii.co.uk,2003:tst.8333983 ')" target="_new" rel="nofollow">http://www.moneyweek.com/investment-advice/penny-shares/penny-stocks-will-lead-a-new-era-for-medicine-539

Penny stocks will lead a new era for medicine

By Tom Bulford May 31, 2011



If you think that a regime of junk food, minimal exercise and pill popping is unlikely to prolong your life, you would be right. It certainly seems to be taking its toll on the American population. Despite spending $10,000 per capita on healthcare every year – twice what we pay in Europe – the life expectancy of the average American has tailed off in recent years.

But a seismic shift in how America handles healthcare is underway. Health authorities are beginning to appreciate that prevention is better than cure. A swing towards preventative medical care could transform healthcare in the US – and indeed across the world.


This is the message of an excellent research note on the healthcare and life sciences sector by Peel Hunt. And I want to pick over the details of this report today – because I think there are serious opportunities here for penny investors…

America’s health is in crisis
You are well familiar with the problem by now. An ageing population demands more healthcare, but this is increasingly hard to afford. Ironically, it is previous improvements in healthcare that have contributed to the problem. The introduction of vaccines and antibiotics boosted the average global life expectancy by ten years between 1960 and 1984, and since then another five years has been added.

Meanwhile, life expectancy in ‘MENA’ (the Middle East and North African region) and in the ‘BRICs’ (Brazil, Russia, China and India) has increased by 20 years since 1960. With an ever growing proportion of elderly people in the world, the outlook for healthcare providers should be excellent. But as investors in the big pharmaceutical companies know to their cost, this is not always translating into good share price performance.

One cause is associated with life expectancy. Although the US population is ageing, it is not ageing as fast as is in other regions. But more than any other nationality, Americans rely upon pills for the correction of their maladies. The USA’s medical bill is already a serious financial and political problem and all but the most selfish interest groups recognise the need for change. The $10,000 per capita the US spends on healthcare accounts for an extraordinary 16% of GDP. This is twice the level seen across Europe, Japan and Australia and yet life expectancy in the US is lower. Since the early 1980s, the USA’s healthcare spending has doubled, and within that, the proportion spent on drugs has tripled. And yet improvements in life expectancy have been waning.

Why I think penny stocks will lead this new era in medicine
Waiting for diseases to materialise and then zapping them with tablets is not the ideal approach to healthcare. In 2007, a report by the Milken Institute called for a change. It argued that the key to tackling the chronic conditions of heart disease, cancer, respiratory disease and diabetes lies with life-style change – basically diet and exercise – and with screening and disease prevention. This switch away from drugs towards preventative healthcare is adding to the pressure on the big drug makers. Already hit by competition from cut-price generic versions of their best selling drugs, they now face pricing pressure from health authorities increasingly desperate to cut costs. They have responded to this by cutting back on their research, the closure of Pfizer’s facility in Sandwich being a case in point.

Claim your special FREE report: 10 simple rules for maximising your penny share profits

Receive the stock market wisdom of a top-level penny share expert
Your essential guide to playing the small caps market

Their strategy now is to let small life science innovators do the risky and expensive work of drug discovery, while seeking to push sales into emerging markets. Peel Hunt doubts that this st By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=8333983&action=detail Wed, 01 Jun 2011 14:34:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.8179655
Strategic acquisitions and organic growth in an expanding market for high quality outsourced sterilisation services mean that turnover and profits are set to continue on a positive upward path for years to come.

A good long term investment which has done me extremely well since I got in originally at under £3 and since have continued to buy regularly.

TS By thorn standing ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=8179655&action=detail Wed, 27 Apr 2011 07:36:00 GMT thorn standing tag:iii.co.uk,2003:tst.8071390
I am pleased that I have not missed any news and you have echoed my thoughts, I too believe this is a good time to buy and SYR is a good long term investment. By silvetici ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=8071390&action=detail Sun, 03 Apr 2011 07:13:00 GMT silvetici tag:iii.co.uk,2003:tst.8062440
Last year they gave a trading update on 26 April and the year before that 20 April, so I'm expecting something similar on timing this year.

It certainly looks like a normal retracement from the healthy run up from the June 2010 low of 546.5p to the 952p high of Feb. There would certainly be some profit taking here.

A similar level of profit taking took place in the run up from April 2009's 298.5p to the 698p high in December of that year, retracing by a similar amount, but this time over a 6 month period.

I've attached a chart that shows the retracement over both periods and a Fibonacci measurement. I've done this on a weekly chart as it cuts out the daily noise and gives a better view of the trend.

http://img823.imageshack.us/img823/6875/screenhunter01mar312030.gif

The market obviously needs some positive news on 2012, as currently I have 11% growth expected by the market, which might be insufficient to sustain the current price and certainly the previous high of 952p.

Unlike the market I take a longer view and see these shares as good value at this price on solid fundamentals, I have been a holder for 6 years and currently see no reason not to hold for a good few years more.

Just some quick thoughts, but hope it helps. By mutandis13 ]]> http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=8062440&action=detail Thu, 31 Mar 2011 20:43:00 GMT mutandis13 tag:iii.co.uk,2003:tst.8057518 http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=8057518&action=detail Thu, 31 Mar 2011 08:55:00 GMT silvetici tag:iii.co.uk,2003:tst.7839382 http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=7839382&action=detail Mon, 21 Feb 2011 12:19:00 GMT mutandis13 tag:iii.co.uk,2003:tst.7838296 http://www.iii.co.uk/investment/detail?code=cotn:SYR.L&display=discussion&id=7838296&action=detail Mon, 21 Feb 2011 09:59:00 GMT silvetici